Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ.
Berenson JR, et al. Among authors: rosen ls.
Cancer. 2001 Apr 1;91(7):1191-200. doi: 10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0.
Cancer. 2001.
PMID: 11283917
Clinical Trial.